Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.

Meyer zu Schwabedissen HE, Albers M, Baumeister SE, Rimmbach C, Nauck M, Wallaschofski H, Siegmund W, Völzke H, Kroemer HK.

Pharmacogenet Genomics. 2015 Jan;25(1):8-18. doi: 10.1097/FPC.0000000000000098.

PMID:
25379722
2.

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Neuvonen PJ, Backman JT, Niemi M.

Clin Pharmacokinet. 2008;47(7):463-74. Review.

PMID:
18563955
3.

No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.

Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, Kolovou G, Manolopoulos VG.

Mol Biol Rep. 2014 Jul;41(7):4631-8. doi: 10.1007/s11033-014-3334-z. Epub 2014 Mar 26.

PMID:
24668570
4.
5.

SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.

Hubáček JA, Dlouhá D, Adámková V, Zlatohlavek L, Viklický O, Hrubá P, Češka R, Vrablík M.

Med Sci Monit. 2015 May 20;21:1454-9. doi: 10.12659/MSM.893007.

6.

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Kivistö KT, Niemi M.

Pharm Res. 2007 Feb;24(2):239-47. Epub 2006 Dec 20. Review.

PMID:
17177112
7.

SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, Deng S, Xie QY, Xie W, Xu LY, Wang LC, Fan L, Wang A, Zhou HH.

Br J Clin Pharmacol. 2007 Sep;64(3):346-52. Epub 2007 Apr 18.

8.

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Niemi M, Pasanen MK, Neuvonen PJ.

Clin Pharmacol Ther. 2006 Oct;80(4):356-66.

PMID:
17015053
9.

Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.

Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrié A.

Pharmacogenomics. 2008 Sep;9(9):1217-27. doi: 10.2217/14622416.9.9.1217.

10.

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.

Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M.

Pharmacogenet Genomics. 2006 Dec;16(12):873-9.

PMID:
17108811
11.

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.

Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT.

Clin Pharmacol Ther. 2006 May;79(5):419-26. Epub 2006 Apr 11.

PMID:
16678544
12.

SLCO1B1 variants and statin-induced myopathy--a genomewide study.

SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R.

N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23.

13.

Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.

Hu M, Tomlinson B.

Atherosclerosis. 2012 Aug;223(2):427-32. doi: 10.1016/j.atherosclerosis.2012.06.002. Epub 2012 Jun 13.

PMID:
22749334
14.

Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.

Mladenovska K, Grapci AD, Vavlukis M, Kapedanovska A, Eftimov A, Geshkovska NM, Nebija D, Dimovski AJ.

Pharmazie. 2017 May 1;72(5):288-295. doi: 10.1801/ph.2017.6960.

PMID:
29441875
15.

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS.

J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16. doi: 10.1016/j.jacc.2009.04.053.

16.

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

Romaine SP, Bailey KM, Hall AS, Balmforth AJ.

Pharmacogenomics J. 2010 Feb;10(1):1-11. doi: 10.1038/tpj.2009.54. Epub 2009 Nov 3. Review.

PMID:
19884908
17.
18.
19.

Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.

Kunze A, Huwyler J, Camenisch G, Poller B.

Drug Metab Dispos. 2014 Sep;42(9):1514-21. doi: 10.1124/dmd.114.058412. Epub 2014 Jul 2.

PMID:
24989890
20.

Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.

Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M.

Pharmacogenet Genomics. 2008 Oct;18(10):921-6. doi: 10.1097/FPC.0b013e32830c1b5f.

PMID:
18794729

Supplemental Content

Support Center